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Abstract
Background: Waiting times for cancer patients are a national priority in the UK. Previous studies
have shown variation between cancer networks in the time between diagnosis and start of
radiotherapy for all cancer patients. Studies of the relationship between delay in receiving
treatment and survival of breast cancer patients have been inconsistent. This study aimed to
examine factors associated with waiting times for radiotherapy for breast cancer patients.
Methods: 35,354 women resident in South East England and diagnosed with breast cancer
between 1992 and 2001 who received radiotherapy within six months of diagnosis were identified
from the Thames Cancer Registry. Time to radiotherapy was measured from either the date of
diagnosis or the start of the previous treatment, whichever was shorter. Unadjusted and adjusted
logistic regression models were fitted to examine whether patients received radiotherapy within
60 days of their diagnosis or previous treatment.
Results: The adjusted proportions of patients receiving radiotherapy within 60 days varied
significantly between different cancer networks (range: 43% to 81%), and decreased from 68% in
1992 to 33% in 2001. After adjustment there was no association between deprivation of area of
residence, age or stage and radiotherapy wait. Median time waited to radiotherapy increased over
the study period whether measured from the start of chemotherapy, hormone therapy, surgery or
the date of diagnosis.
Conclusion: This study covered a period of time before the investment following the Cancer Plan
of 2000. Results are consistent with other findings suggesting variation between cancer networks
and increasing waits over time. Further studies should examine different methods of measuring
waiting time, the causes and consequences of waits for radiotherapy and the effect of current
initiatives and investments.
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In recent years the National Health Service in England and
Wales has focused attention and considerable resources on
reducing waiting times for cancer patients. In 2000 a large
survey [1] based on cases diagnosed in 1997 found that the
waiting times of patients with cancer in England varied
across regions. The shortest waits were found for patients
with breast cancer, who waited a median of 14 days from
referral to their first outpatient appointment and 35 days to
first definitive treatment. This group was the first for whom
a maximum two-week wait between urgent referral and first
appointment at hospital was proposed [2]. Implementa-
tion began in 1999 and the national cancer waiting times
database now shows that nearly all urgently referred breast
cancer patients are seen within two weeks [3]. As this first
target has been met, attention has turned to the wait
between diagnosis and treatment. A further target of a max-
imum one-month wait from diagnosis to treatment was
also met for 99.7% of patients in the last quarter of 2005/
2006, and a one-month wait from urgent referral to begin-
ning of treatment for all cancers has been proposed for the
year 2008 [3,4].
The importance of reducing the length of time between first
symptoms and treatment of breast cancer was strongly sug-
gested by a systematic review by Richards et al [5]. These
authors reviewed 87 studies of breast cancer, including data
on over 100,000 patients. They found that those patients
who had waited three months or more from first symptoms
to treatment had 12% lower survival than those waiting
shorter periods. However, the patients with the longer
delays were more likely to have advanced stage of disease
by the time they reached treatment. Once the effect of stage
was taken into account, delays were not associated with
reduced survival. A study of patients in Yorkshire demon-
strated that breast cancer patients waiting more than 30
days between family physician referral and treatment had
better survival than those waiting 30 days or less [6].
The relationship between delay in diagnosis and treatment
(whether attributable to the patient, the doctor or the
health care system), and survival from breast cancer is com-
plex. At each point from initial symptoms to definitive
treatment, the decisions and actions of patients and doctors
may be influenced by their assessment of the severity of
symptoms, the treatment needed and the services available.
For example, one Danish study found that patients for
whom the delay attributable to the doctor had been longer
had a better prognosis than those for whom it had been
shorter. This suggested that doctors identified patients with
more aggressive breast tumours and sent them through the
system more quickly [7]. Similarly, one German study
found that the relationship between stage of disease at diag-
nosis and delay before treatment showed a U-shaped asso-
ciation. Women with either very short or very long delays
had the highest proportions of late-stage tumours. This sug-
gested that women presenting with a clear clinical picture
of later stage disease may have been diagnosed and treated
more quickly, while those presenting with very early symp-
toms (and a less clear clinical picture) may have initially
received a delayed diagnosis and therefore reached treat-
ment with more advanced disease [8]. In a study of women
with breast cancer in South East England, Robinson et al [9]
found that the length of wait from first hospital appoint-
ment to first treatment was highly dependent on what that
first treatment was. The group for whom this was radiother-
apy experienced the longest delays, with just over half
receiving treatment within five weeks of first hospital
appointment. A recent study by Mikeljevic et al [10] found
that patients treated with conservative surgery had a higher
mortality if they waited longer than nine weeks for subse-
quent radiotherapy.
In a study of waiting times for radiotherapy in patients
diagnosed with cancer between 1992 and 2001 in South
East England we found variation across cancer networks
and different cancer sites [11]. The difference in waiting
times between networks persisted after adjustment for age,
sex, cancer site, socioeconomic deprivation and year of
diagnosis, with the proportion receiving radiotherapy
within 60 days of diagnosis ranging from 44% to 71%.
Repeating the analysis using a 'truncated' waiting time (that
from diagnosis or the last treatment received before radio-
therapy), we found generally shorter waits but a similar pat-
tern of variation. The study also revealed a significant
increase in waiting times between 1992 and 2001. This
increase is consistent with a recent report from the Royal
College of Radiologists which found that between 1998
and 2002, towards the end of our study period, the propor-
tion of patients waiting longer than four weeks to start
potentially curative radical radiotherapy had increased
from 28% to 81% across the UK [12].
This paper concentrates on patients diagnosed with breast
cancer in South East England between 1992 and 2001 who
received radiotherapy within six months of diagnosis. Our
aim was to examine in more detail the factors influencing
whether patients with breast cancer received radiotherapy
within 60 days of their diagnosis or previous treatment.
Methods
Data
In the United Kingdom, cancer registries record the occur-
rence of cancer in their resident populations as well as treat-
ments given in the first six months after diagnosis.
Registration is initiated by clinical and pathology informa-
tion received from hospitals and by information about
deaths provided by the National Health Service Central
Register through the Office for National Statistics. Data col-
lection officers collect further information on demographicPage 2 of 8
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records. Data are quality assured as they are added to the
central database. The date of diagnosis is defined as the date
on which cancer was confirmed by the most precise of the
diagnostic tests performed (ideally histological or cytologi-
cal confirmation) or, if not available, the date of admission
to hospital for the malignancy or, if there was no admis-
sion, the date of first outpatient consultation. During the
period of study the Thames Cancer Registry covered the
population of an area of South East England covering Essex,
Hertfordshire, London, Kent, Surrey and Sussex.
Records on female patients registered with breast cancer
(invasive or in situ) at Thames Cancer Registry who were
diagnosed between 1992 and 2001 were examined. Of the
95,118 eligible patients, 35,354 (37%) received radiother-
apy within six months of diagnosis, and this subgroup was
used in all further analyses. A relatively small number of
patients (n = 725, 0.8%) were excluded from the study at
the outset either because the date recorded for their diagno-
sis appeared to be after their radiotherapy or after their
death, or because their recorded date of radiotherapy was
after their death.
Age was divided into ten-year groups. The staging data
available to the registry relies on that recorded by clinicians
within the medical records. Because this is often not com-
pletely recorded, the registry uses all the information that it
can obtain to classify stage using a simplified system based
on the WHO Extension of Disease Classification. This "TCR
staging" is: 1) 'localised'; 2) 'extension beyond the organ of
origin'; 3) 'local lymph node involvement'; 4) 'metastases';
or 'not known'. Postcode of residence at diagnosis was used
to determine cancer network and ward of residence. Socio-
economic deprivation of the patient's area of residence was
estimated by a ward level quintile of the income score part
of the Indices of Multiple Deprivation (IMD) [13].
Analysis
This study follows similar methodology to that used in the
previous analysis of all cancer patients [11]. Time to radio-
therapy was measured from either the date of diagnosis or
the start of the most recent previous treatment, whichever
was shorter. If a patient's first treatment was radiotherapy
we measured the time they waited to radiotherapy from the
date of their diagnosis. For patients who received another
treatment first, we used the start date of the treatment they
received immediately before radiotherapy. This definition
was used as radiotherapy tends to be given after other ther-
apies, and the waiting time from date of diagnosis only may
be exaggerated by waits for other treatments. While it
would be preferable to measure time waited to radiother-
apy starting at the date other treatments were completed,
particularly chemotherapy [14], unfortunately this infor-
mation is not available in the Thames Cancer Registry data-
set.
The median waiting time between diagnosis or previous
treatment and the start of radiotherapy was calculated,
stratified by whether this was measured from start of chem-
otherapy, hormone therapy, surgery or the date of diagno-
sis (if radiotherapy was the first treatment received).
Logistic regression models were fitted to examine which
factors affected whether the patient received radiotherapy
within 60 days of diagnosis or previous treatment. A fully
adjusted model was fitted, including cancer network of res-
idence, year of diagnosis, site (invasive or in situ), stage,
IMD income quintile, age group, and a variable indicating
whether the patient survived six months after diagnosis.
The latter was included to allow for the fact that short-term
survivors who had been given radiotherapy would of neces-
sity receive it soon after diagnosis. All results from logistic
regression modelling were transformed to give crude and
adjusted proportions receiving radiotherapy within 60 days
of diagnosis or previous treatment. The 60-day target was
chosen to be consistent with our previous work [11] and, as
around 60% of patients met the target, this cut-off point
provided adequate statistical power for our analysis. Tests
for trend were done by fitting categorical variables as con-
tinuous, and chi2 tests were used to test for heterogeneity,
excluding other and not known categories.
Results
Figure 1 shows the waiting times from diagnosis or previ-
ous treatment for the main types of treatment received by
patients with breast cancer. The waiting times for surgery,
hormone therapy and chemotherapy were short and more
than 80% of patients waited less than 60 days for these
treatments. There was little change in these waits over the
study period. The waiting times for radiotherapy, however,
were longer and the proportion of patients that received
radiotherapy within 60 days decreased from more than
60% in the early 1990s to less than 40% in 2001. The vari-
ation in waiting time for radiotherapy is the subject of all
subsequent analyses.
The proportions of patients receiving radiotherapy within
60 days of their diagnosis or previous treatment are
shown in Table 1, both unadjusted and adjusted for all
other variables. There was a highly significant variation in
the proportions in relation to cancer network of residence.
Between 45% and 79% of patients were treated within 60
days. These proportions corresponded to median waits
ranging from 36 to 65 days in different networks. Statisti-
cal adjustment had no material influence on this variation
between cancer networks (Figure 2).
There was an increase in median wait for radiotherapy
over time from 43 days in 1992 to 77 days in 2001. ThisPage 3 of 8
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the proportions of patients receiving radiotherapy within
60 days (from 68% in 1992 to 36% in 2001). This varia-
tion in waiting times over the study period was not mate-
rially influenced by statistical adjustments (Figure 3).
Figure 4 shows the median time waited to radiotherapy,
whether this was measured from the start of chemother-
apy, hormone therapy, surgery or the date of diagnosis.
Although patients who received chemotherapy immedi-
ately before radiotherapy consistently had the longest
waits, the time to waited for radiotherapy increased in the
later period in all groups.
Patients with invasive cancer were significantly more likely
to receive radiotherapy within 60 days (60%) than those
with carcinoma in situ (50%) (p < 0.0001). This difference
was again unchanged after adjustment for other variables.
The association between stage of disease and wait for radi-
otherapy was more complex. The unadjusted proportions
indicated that patients with metastases were more likely to
receive radiotherapy within 60 days than other patients.
However, after adjusting for other variables this difference
became statistically non-significant. The attenuation of this
stage effect in the adjusted analysis was mainly due to
adjustment for survival, which is very closely associated
with stage. There were no differences in waiting time
between socioeconomic groups or between age groups.
Discussion
This study of breast cancer patients treated with radiother-
apy in South East England found an increase in the time
they had waited after their diagnosis or previous treatment
before receiving radiotherapy over the period 1992 to
2001. Considerable variation in waiting times for radio-
therapy between cancer networks also emerged. Both find-
ings were robust to adjustment for case mix factors
including age, stage and deprivation of area of residence.
There are a number of factors to consider in interpreting the
results of this study, some of which we were not able to
measure. Firstly, increasing waits could be partially
explained by a heavier overall workload or increasing com-
plexity of treatment in radiotherapy departments over time.
We could only include patients in this study if they received
radiotherapy within six months of diagnosis, as this is the
full follow-up period for collection of treatment informa-
tion by the registry. Radiotherapy received after this period
would not have been recorded in the database, but would
still contribute to an increased workload in radiotherapy
departments within networks. Patients included in this
study will not be representative of all patients receiving
radiotherapy, but relate to patients receiving radiotherapy
as part of their initial treatment. Although the numbers of
all cancer patients being treated with radiotherapy within
six months of diagnosis was fairly constant for South East
England [11], treatment is likely to have become more
complex over the study period and require more detailed
planning. For example, a study by the Royal College of
Radiologists [15] found that between 1992 and 1997 the
number of new patients had increased by 8.6%, whereas
the number of exposures had risen by 18%.
Secondly, we attempted to assess the "true" wait for radio-
therapy for patients who had received other treatments
before radiotherapy by measuring their waiting time from
the start of the last treatment before radiotherapy. How-
ever, this approach does not overcome all problems. Only
the start date of the previous treatment was available, so the
duration of that treatment and of any recovery time were
included within the wait. This will have affected the wait
from chemotherapy to radiotherapy in particular, as chem-
otherapy can be a lengthy treatment. However, we found
that the increase in wait over time was seen whether the
previous treatment was chemotherapy, hormone therapy
or surgery as well as when radiotherapy was itself the first
treatment received after diagnosis. The time taken by fur-
ther investigations after diagnosis and before treatment will
also be included in the wait measured here. Increasing
waits for these investigations could in turn be contributing
to longer waits for radiotherapy.
Thirdly, while adjustment for several important variables
did not explain the variation over time or between net-
Proportion of patients receiving different types of treatment within 60 days of diagnosis or previous treatment by year ofdiagn sisFigure 1
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Table 1: Median waiting times and proportion of patients receiving radiotherapy (RT) within 60 days of diagnosis or previous 
treatment
Total number of patients Number(%) receiving RT Median wait (days) % treated within 60 days after diagnosis or previous treatment
Unadjusted Adjusteda
Network of residence
Ab 1940 489 (25) 36 79 81
B 11527 4685 (41) 61 49 47
Cb 4626 1716 (37) 48 63 66
Db 7239 3190 (44) 56 55 53
E 8154 2924 (36) 49 63 59
F 7196 2665 (37) 49 62 61
G 8768 2976 (34) 56 54 53
H 5171 1806 (35) 42 76 77
I* 8915 2977 (33) 44 68 68
J 9793 3572 (36) 48 63 63
K 9396 3000 (32) 65 45 43
Lb 2111 650 (31) 55 60 56
M 10197 4677 (46) 48 63 62
Other/Not known 85 27 (32) 55 63 64
Test for heterogeneity: χ2 (12 df) 958.9 1046.7
p < 0.0001 p < 0.0001
Year of diagnosis
1992* 9163 3555 (39) 43 68 68
1993 8403 3099 (37) 45 67 67
1994 8911 3530 (40) 45 69 69
1995 9228 3718 (40) 47 67 66
1996 9937 3935 (40) 49 63 62
1997 10362 4134 (40) 51 61 60
1998 10011 3672 (37) 51 61 59
1999 9944 3667 (37) 56 54 52
2000 9693 3127 (32) 69 42 40
2001 9466 2917 (31) 77 36 33
Test for trend: χ2 (1 df) 1229.7 1329.0
p < 0.0001 p < 0.0001
Site
Breast* 89163 34162 (38) 51 60 60
Breast in situ 5955 1192 (20) 60 50 50
Test for heterogeneity: χ2 (1 df) 42.2 37.7
p < 0.0001 p < 0.0001
Stage
1* 38870 16969 (44) 54 58 58
2 1955 747 (38) 51 58 53
3 17201 7568 (44) 55 56 54
4 4947 1661 (34) 31 73 68
Not known 32145 8409 (26) 47 63 59
Test for trend: χ2 (1 df) 20.8 0.8
p < 0.0001 p = 0.3660
IMD income quintile
1 (Least deprived)* 19996 7854 (39) 50 61 61
2 20010 7600 (38) 51 59 59
3 19058 7211 (38) 53 58 59
4 19175 6914 (36) 52 59 59
5 (Most deprived) 16759 5756 (34) 51 59 59
Not known 120 19 (16) 55 58 62
Test for trend: χ2 (1 df) 1.8 1.6
p = 0.1783 p = 0.2050
Age group
< 50* 19883 8329 (42) 51 59 59
50–59 23091 10483 (45) 50 60 62
60–69 19463 9170 (47) 53 60 62
70–79 17581 5882 (33) 53 58 60
80+ 15100 1490 (10) 52 58 59
Test for trend: χ2 (1 df) 0.3 1.4
p = 0.5828 p = 0.2456
All cases 95118 35354 (37) 52 59
a = Adjusted for all other variables in table and survival
b = TCR part of network
* = Baseline category
Tests for heterogeneity and trend exclude 'other' and 'not known' categories
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which was not known for 24% of patients receiving radio-
therapy. Other factors which would have an important
influence on time waited to radiotherapy, such as comor-
bidity, are not available in the Thames Cancer Registry data-
set and could not be included in this study. Those with
metastatic disease would receive palliative, rather than cur-
ative, radiotherapy, and would therefore be treated more
quickly. The fact that patients with the less severe breast
cancer in situ waited longer for radiotherapy highlights the
fact that the observed differences will often be a conse-
quence of clinical decisions.
It is a weakness of the cancer registration data that only
treatment episodes within the six month period following
diagnosis are routinely recorded. From the incomplete
records we have of later treatments, it is evident that an
increasing proportion of breast cancer patients received
radiotherapy later than six months after diagnosis. The
effect of this artefact is conservative with respect to our find-
ing of a trend towards longer waits for radiotherapy, but it
also implies that the women who received radiotherapy
seven months after diagnosis or later were entirely missed
in the analysis. As the time to treatment increases beyond
six months, it becomes more difficult to decide whether the
radiotherapy was a primary or a secondary treatment
choice. In the future it is hoped that cancer registries will
include not only treatments and their dates but also treat-
ment decisions and their dates, as this would facilitate wait-
ing times analysis, particularly when the waits are long.
Studies which break down the overall time between disease
detection and adjuvant treatment into distinct stages are
able to identify where intervals are increasing over time
[16].
Our findings can be compared to several recent studies
which have examined waiting times for radiotherapy. A UK
national audit of radiotherapy waiting times for all cancer
patients showed an increase in the proportion of patients
waiting longer than the Joint Collegiate Council for Oncol-
ogy maximum acceptable standard for radical, palliative
and adjuvant treatments between 1998 and 2003 [17]. In
our earlier study of all cancer patients for the period 1992
and 2001 we found a similar trend of increasing waits for
all cancers [11]. Studies that have looked specifically at
breast cancer have also found increasing waiting times over
time. For example, time from diagnosis to radiotherapy
increased for breast cancer patients in Canada between
1992 and 2000 [18], and Mikeljevic et al [10] showed that
the wait from breast-conserving surgery to radiotherapy in
Yorkshire, UK had increased between 1986 and 1998.
Variation between cancer networks was previously seen for
all cancer sites in South East England [11]. The UK study in
Proportion of patients receiving radiotherapy within 60 days of diagnosis r previous tr atment by year of diagnosisFigure 3
Proportion of patients receiving radiotherapy within 60 days 
of diagnosis or previous treatment by year of diagnosis
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
Year of diagnosis
Unadjusted
Adjusted*
*Adjusted for cancer network of residence, site, stage, socioeconomic 
deprivation, age and 6-month survival.
Proportion of patients receiving radiotherapy within 60 days of diagnosis r previous tr atment by cancer network of re -idenceFigure 2
Proportion of patients receiving radiotherapy within 60 days 
of diagnosis or previous treatment by cancer network of res-
idence
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
A B C D E F G H I J K L M
Cancer Network of Residence
Unadjusted
Adjusted*
*Adjusted for year of diagnosis, site, stage, socioeconomic deprivation, age 
and 6-month survival.Page 6 of 8
(page number not for citation purposes)
BMC Cancer 2007, 7:71 http://www.biomedcentral.com/1471-2407/7/71Yorkshire also found variation between hospital trusts in
the time from breast-conserving surgery to radiotherapy for
patients who did not have chemotherapy [10]. This again
confirmed findings from an earlier study in Yorkshire
showing variation in treatment between districts [19].
Studies of the relationship between delay in receiving treat-
ment and survival have been inconsistent [20]. One sys-
tematic review found that a longer interval between the
onset of symptoms and treatment was linked to worse sur-
vival [5]. However when studies restricted the period of
waiting to periods involving health services, for example
time between family doctor referral and treatment [6] or
date first seen to diagnosis [5], better survival was found in
patients with longer waits.
Advanced booking of radiotherapy, for example at the time
of the multi-disciplinary team meeting, may reduce time
spent waiting for treatment. Patient numbers and length of
treatment should be monitored and forecast to ensure staff
and equipment levels are adequate.
The UK Cancer Plan was launched in 2000 [21], and recog-
nised very clearly that substantial improvement was needed
in the provision of radiotherapy services. It is unlikely that
the investment that followed this plan would have begun
to have an effect in the years 2000 and 2001 included in the
last part of our study period. However, as some observers
have raised concerns that this investment might not be suf-
ficient [22], close monitoring of the situation will be
needed. Future studies should seek to measure the waits for
radiotherapy after referral more directly, compare these to
those that can be calculated from registry records and
understand their causes and possible consequences. One
approach to understanding the apparent variation in wait-
ing times between cancer networks would be to compare
the workload (number of patients referred and treated) and
capacity (use of staff and equipment) of different trusts to
Median time to radiotherapy (days) by year of diagnosis, whether measured from start of chemotherapy, hormone therapy, surgery or date of diagnosisFigure 4
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ciently carried out by detailed case studies of several trusts
or networks that appear to have widely differing waits. The
effect of cancer networks on waiting times for radiotherapy
should be explored further, for example by looking at vari-
ation within networks, the effect of the size of population
covered or treated, or distance to the radiotherapy suite.
The possible influence of these waiting times on survival
for patients with breast cancer of different stage will need to
be explored in detail and reviewed as current policy initia-
tives begin to take effect.
Future studies should explore the effect of different treat-
ment choices on waiting times for radiotherapy, for exam-
ple type of surgery and whether chemotherapy was received
or not, as the role of radiotherapy is influenced by these fac-
tors. In addition, the effect of treatment delays on outcomes
(particularly survival) should be examined in detail.
Conclusion
The findings of increasing time to radiotherapy for women
with breast cancer in South East England and variation in
time waited between cancer networks suggests that better
planning and more investment in radiotherapy services are
needed. Further studies should explore the association
between waiting time and survival and the psychological
impact of long waits for radiotherapy.
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